Legal & General Group PLC Chinook Therapeutics, Inc. Transaction History

Legal & General Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $524,887 - $1.09 Million	28,129 Added 122.17%	51,153 $1.97 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $143,755 - $178,943	6,677 Added 40.85%	23,024 $533,000
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $14,307 - $21,004	768 Added 4.93%	16,347 $428,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $16,809 - $22,435	960 Added 6.57%	15,579 $306,000
Q2 2022 Aug 22, 2022	BUY	$12.59 - $18.8 $141,209 - $210,860	11,216 Added 329.59%	14,619 $256,000
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $3,774 - $5,240	314 Added 10.17%	3,403 $56,000
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $4,094 - $6,445	383 Added 14.15%	3,089 $50,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $2,254 - $2,912	196 Added 7.81%	2,706 $35,000
Q2 2021 Aug 12, 2021	BUY	$13.6 - $18.98 $14,620 - $20,403	1,075 Added 74.91%	2,510 $35,000
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $1,686 - $2,274	-119 Reduced 7.66%	1,435 $22,000
Q4 2020 Feb 12, 2021	BUY	$11.9 - $20.91 $18,492 - $32,494	1,554 New	1,554 $25,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.